Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Rhabdomyolysis following a short course of clarythromycin.

Schor AM, Hellerstein A.

J Pediatr Pharmacol Ther. 2011 Jul;16(3):216-7. doi: 10.5863/1551-6776-16.3.216.

2.

Biomaterials in regenerative medicine: engineering to recapitulate the natural.

Keatch RP, Schor AM, Vorstius JB, Schor SL.

Curr Opin Biotechnol. 2012 Aug;23(4):579-82. doi: 10.1016/j.copbio.2012.01.017. Epub 2012 Mar 14. Review.

PMID:
22421635
3.

Bistable switch in migration stimulating factor expression: regulation by the concerted signalling of transforming growth factor-β1 and the extracellular matrix.

Schor SL, Ellis IR, Jones SJ, Woolston AM, Schor AM.

Int J Cancer. 2012 May 1;130(9):2024-32. doi: 10.1002/ijc.26213. Epub 2011 Aug 16.

4.

Migration-stimulating factor as a novel biomarker in salivary gland tumours.

Aljorani LE, Bankfalvi A, Carey FA, Harada K, Ohe G, Jones SJ, Ellis IR, Schor SL, Schor AM.

J Oral Pathol Med. 2011 Nov;40(10):747-54. doi: 10.1111/j.1600-0714.2011.01044.x. Epub 2011 Apr 11.

PMID:
21481007
5.

Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT.

Ellis IR, Jones SJ, Lindsay Y, Ohe G, Schor AM, Schor SL, Leslie NR.

Cell Signal. 2010 Nov;22(11):1655-9. doi: 10.1016/j.cellsig.2010.06.005. Epub 2010 Jul 1.

PMID:
20600851
6.

Multi-factorial modulation of IGD motogenic potential in MSF (migration stimulating factor).

Ellis IR, Jones SJ, Staunton D, Vakonakis I, Norman DG, Potts JR, Milner CM, Meenan NA, Raibaud S, Ohea G, Schor AM, Schor SL.

Exp Cell Res. 2010 Sep 10;316(15):2465-76. doi: 10.1016/j.yexcr.2010.04.003. Epub 2010 Apr 18.

PMID:
20403349
7.

Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention.

Schor AM, Schor SL.

Eye (Lond). 2010 Mar;24(3):450-8. doi: 10.1038/eye.2009.314. Epub 2009 Dec 18. Review.

PMID:
20019766
8.

Motogenic sites in human fibronectin are masked by long range interactions.

Vakonakis I, Staunton D, Ellis IR, Sarkies P, Flanagan A, Schor AM, Schor SL, Campbell ID.

J Biol Chem. 2009 Jun 5;284(23):15668-75. doi: 10.1074/jbc.M109.003673. Epub 2009 Apr 14.

9.

Assessment of vascularity as an index of angiogenesis in periradicular granulomas. Comparison with oral carcinomas and normal tissue counterparts.

Davey KJ, Perrier S, Ohe G, Gilbert AD, Bankfalvi A, Saunders WP, Schor SL, Schor AM.

Int Endod J. 2008 Nov;41(11):987-96. doi: 10.1111/j.1365-2591.2008.01466.x.

PMID:
19133088
10.

Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.

Motegi K, Harada K, Ohe G, Jones SJ, Ellis IR, Crouch DH, Schor SL, Schor AM.

Exp Cell Res. 2008 Aug 1;314(13):2323-33. doi: 10.1016/j.yexcr.2008.04.013. Epub 2008 May 9.

PMID:
18555217
11.

Individually addressable microelectrode array for monitoring oxygen and nitric oxide release.

Patel BA, Arundell M, Quek RG, Harvey SL, Ellis IR, Florence MM, Cass AE, Schor AM, O'Hare D.

Anal Bioanal Chem. 2008 Mar;390(5):1379-87. doi: 10.1007/s00216-007-1803-0. Epub 2008 Jan 10.

PMID:
18185922
12.

Co-expression by keratinocytes of migration stimulating factor (MSF) and a functional inhibitor of its bioactivity (MSFI).

Jones SJ, Florence MM, Ellis IR, Kankova K, Schor SL, Schor AM.

Exp Cell Res. 2007 Dec 10;313(20):4145-57. Epub 2007 Sep 21.

PMID:
17949711
13.

The role of the fibronectin IGD motif in stimulating fibroblast migration.

Millard CJ, Ellis IR, Pickford AR, Schor AM, Schor SL, Campbell ID.

J Biol Chem. 2007 Dec 7;282(49):35530-5. Epub 2007 Oct 5.

14.

EGF AND TGF-alpha motogenic activities are mediated by the EGF receptor via distinct matrix-dependent mechanisms.

Ellis IR, Schor AM, Schor SL.

Exp Cell Res. 2007 Feb 15;313(4):732-41. Epub 2006 Dec 5.

PMID:
17196962
15.

Synthesis of an IGD peptidomimetic with motogenic activity.

Shpiro N, Ellis IR, Dines TJ, Schor AM, Schor SL, Norman DG, Marquez R.

Mol Biosyst. 2005 Oct;1(4):318-20. Epub 2005 Aug 26.

PMID:
16880997
16.

A novel 'sandwich' assay for quantifying chemo-regulated cell migration within 3-dimensional matrices: wound healing cytokines exhibit distinct motogenic activities compared to the transmembrane assay.

Schor SL, Ellis IR, Harada K, Motegi K, Anderson AR, Chaplain MA, Keatch RP, Schor AM.

Cell Motil Cytoskeleton. 2006 May;63(5):287-300.

PMID:
16528704
17.
18.

Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues.

Macluskey M, Baillie R, Morrow H, Schor SL, Schor AM.

Br J Oral Maxillofac Surg. 2006 Apr;44(2):116-23.

PMID:
15908066
19.

Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells.

Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, Motegi K, Vojtesek B, Kankova K, Furrie E, Sales MJ, Schor AM, Kay RA.

Cancer Res. 2003 Dec 15;63(24):8827-36.

20.

Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.

Motegi K, Harada K, Pazouki S, Baillie R, Schor AM.

Histochem J. 2002 Aug-Sep;34(8-9):411-21.

PMID:
12814189
21.

Growth factors in the treatment of diabetic foot ulcers.

Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL.

Br J Surg. 2003 Feb;90(2):133-46. Review.

PMID:
12555288
22.

Phenotypic and genetic alterations in mammary stroma: implications for tumour progression.

Schor SL, Schor AM.

Breast Cancer Res. 2001;3(6):373-9. Epub 2001 Sep 6. Review.

23.

Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies.

Baillie R, Harada K, Carlile J, Macluskey M, Schor SL, Schor AM.

Histochem J. 2001 May;33(5):287-94.

PMID:
11563542
24.

Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.

Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM.

J Oral Pathol Med. 2001 Sep;30(8):449-57.

PMID:
11545235
25.

VEGF expression in skin warts. Relevance to angiogenesis and vasodilation.

Harada K, Baillie R, Lu S, Syrjänen S, Schor AM.

Arch Dermatol Res. 2001 May;293(5):233-8.

PMID:
11409567
26.

Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer.

Baillie R, Carlile J, Pendleton N, Schor AM.

J Clin Pathol. 2001 Feb;54(2):116-20.

27.

Angiogenesis and vasodilation in skin warts. Association with HPV infection.

Harada K, Lu S, Chisholm DM, Syrjänen S, Schor AM.

Anticancer Res. 2000 Nov-Dec;20(6B):4519-23.

PMID:
11205298
28.

Chemotaxis and Chemokinesis in 3D Macromolecular Matrices : Relevance to Angiogenesis.

Schor AM, Ellis I, Schor SL.

Methods Mol Med. 2001;46:163-83. doi: 10.1385/1-59259-143-4:163.

PMID:
21340919
29.

Collagen gel assay for angiogenesis : induction of endothelial cell sprouting.

Schor AM, Ellis I, Schor SL.

Methods Mol Med. 2001;46:145-62. doi: 10.1385/1-59259-143-4:145.

PMID:
21340918
30.

High levels of apoptosis are associated with improved survival in non-small cell lung cancer.

Macluskey M, Baillie R, Chandrachud LM, Pendleton N, Schor AM.

Anticancer Res. 2000 May-Jun;20(3B):2123-8.

PMID:
10928164
31.

Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression.

Macluskey M, Chandrachud LM, Pazouki S, Green M, Chisholm DM, Ogden GR, Schor SL, Schor AM.

J Pathol. 2000 Aug;191(4):368-75.

PMID:
10918211
32.

The presence of pericytes and transitional cells in the vasculature of the human dental pulp: an ultrastructural study.

Carlile MJ, Sturrock MG, Chisholm DM, Ogden GR, Schor AM.

Histochem J. 2000 Apr;32(4):239-45.

PMID:
10872889
33.

The association between epithelial proliferation and disease progression in the oral mucosa.

Macluskey M, Ogden GR, Green M, Chisholm DM, Schor SL, Schor AM.

Oral Oncol. 1999 Jul;35(4):409-14.

PMID:
10645407
34.

Motogenic activity of IGD-containing synthetic peptides.

Schor SL, Ellis I, Banyard J, Schor AM.

J Cell Sci. 1999 Nov;112 ( Pt 22):3879-88.

35.

Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours.

Schor AM, Pendleton N, Pazouki S, Smither RL, Morris J, Lessan K, Heerkens E, Chandrachud LM, Carmichael G, Adi M, Chisholm DM, Stevenson H.

Histochem J. 1998 Dec;30(12):849-56.

PMID:
10100727
36.

Relationships between different measurements of vascularity and clinico-pathological parameters in breast cancer.

Pendleton N, Pazouki S, Heerkens E, Smither RL, Chisholm DM, Moore JV, Howell A, Horan MA, Schor AM.

Anticancer Res. 1998 Nov-Dec;18(6B):4565-8.

PMID:
9891519
37.

Heterogeneity in microvascular density in lung tumours: comparison with normal bronchus.

Schor AM, Pazouki S, Morris J, Smither RL, Chandrachud LM, Pendleton N.

Br J Cancer. 1998 Mar;77(6):946-51.

38.

The association between tumour progression and vascularity in the oral mucosa.

Pazouki S, Chisholm DM, Adi MM, Carmichael G, Farquharson M, Ogden GR, Schor SL, Schor AM.

J Pathol. 1997 Sep;183(1):39-43.

PMID:
9370945
39.

Relationship between vascularity, age and survival in non-small-cell lung cancer.

Chandrachud LM, Pendleton N, Chisholm DM, Horan MA, Schor AM.

Br J Cancer. 1997;76(10):1367-75.

40.

Substratum-dependent stimulation of fibroblast migration by the gelatin-binding domain of fibronectin.

Schor SL, Ellis I, Dolman C, Banyard J, Humphries MJ, Mosher DF, Grey AM, Mould AP, Sottile J, Schor AM.

J Cell Sci. 1996 Oct;109 ( Pt 10):2581-90.

41.

Biphasic effect of thrombospondin-1 (TSP-1) in the regulation of angiogenesis in human breast carcinoma.

Pazouki S, Pendleton N, Heerkens E, Smither RL, Moore JV, Schor AM.

Biochem Soc Trans. 1996 Aug;24(3):368S. No abstract available.

PMID:
8878912
42.

Association of thrombospondin-1 with osteogenic differentiation of retinal pericytes in vitro.

Canfield AE, Sutton AB, Hoyland JA, Schor AM.

J Cell Sci. 1996 Feb;109 ( Pt 2):343-53.

43.

Pericyte differentiation.

Schor AM, Canfield AE, Sutton AB, Arciniegas E, Allen TD.

Clin Orthop Relat Res. 1995 Apr;(313):81-91.

PMID:
7543836
44.

Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells.

Canfield AE, Schor AM.

J Cell Sci. 1995 Feb;108 ( Pt 2):797-809.

45.

Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma.

Schor AM, Rushton G, Ferguson JE, Howell A, Redford J, Schor SL.

Int J Cancer. 1994 Oct 1;59(1):25-32.

PMID:
7927899
46.

Alpha- and beta-xylosides modulate the synthesis of fibronectin and thrombospondin-1 by endothelial cells.

Canfield AE, Sutton AB, Hiscock DR, Gallagher JT, Schor AM.

Biochim Biophys Acta. 1994 Aug 18;1200(3):249-58.

PMID:
8068710
47.

Heterogeneity in collagen biosynthesis by sprouting retinal endothelial cells.

Canfield AE, Schor AM.

J Cell Physiol. 1994 Apr;159(1):19-28.

PMID:
7511145
48.

Fetal-like fibroblasts: their production of migration-stimulating factor and role in tumor progression.

Schor SL, Grey AM, Ellis I, Schor AM, Howell A, Sloan P, Murphy R.

Cancer Treat Res. 1994;71:277-98. Review. No abstract available.

PMID:
7946952
49.

Breast cancer, desmoid tumours, and familial adenomatous polyposis.

Schor SL, Schor AM, Howell A, Crowther D.

Lancet. 1993 Dec 18-25;342(8886-8887):1560; author reply 1561. No abstract available.

PMID:
7902939
50.

Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer.

Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM.

Eur J Cancer. 1993;29A(8):1141-5.

PMID:
8390846

Supplemental Content

Loading ...
Support Center